drugset / Trial / NCT01876641
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
Timeline
- Start
- 2013-10
- Primary completion
- 2018-06
- Completion
- 2018-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | — | — |
| Subject | Decitabine | Small molecule | — | Subcutaneous |
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |